MedTrace Logo

Evaluation of the Haemostatic Agent Purabond in ENT TORS

NCT05405907 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2022-06-06

No results posted yet for this study

Summary

To evaluate the use of Purabond in ENT TORS for diagnostic and therapeutic procedures. Consecutive patients enrolled retrospectively via case note review. Outcome measures - primary and secondary haemorrhage, swallowing outcomes, need for nasogastric tube or tracheostomy, readmission.

Conditions

Interventions

OTHER

PuraBond haemostatic agent

Application of Purabond to surgical field

Sponsors & Collaborators

  • University Hospital Birmingham NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Keshav Gupta, MBBS · ENT registrar

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-05-01
Completion
2022-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05405907 on ClinicalTrials.gov